Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2026-11-13

Summary

This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents and is used to reduces pain. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving celecoxib with durvalaumab and tremellimumab may better treat patients with advanced or metastatic liver cancer.

• Phase: PHASE2

Details

• Lead Sponsor: Emory University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Antigens; Biopsy; Celecoxib; Disulfides; durvalumab; Immunoglobulin G; Magnetic Resonance Spectroscopy; Specimen Handling; tremelimumab